Related Experiment Video
Updated: Jul 10, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Pharmacokinetic variability of anticancer agents.
Samir D Undevia1, Gonzalo Gomez-Abuin, Mark J Ratain
1Cancer Research Center, The University of Chicago, 5841 South Maryland Avenue, MC 2115 Chicago, Illinois 60637, USA.
Nature Reviews. Cancer
|June 2, 2005
Summary
Reducing pharmacokinetic variability in cancer drug therapy is crucial. Understanding patient factors and using mathematical models can help tailor drug doses for better outcomes and reduced toxicity.
Area of Science:
- Pharmacology
- Oncology
- Drug Development
Background:
- Pharmacokinetic variability complicates cancer drug translation, leading to unpredictable toxicity and variable efficacy.
- Genetic polymorphisms and other factors significantly impact drug disposition, affecting treatment outcomes.
- Current approaches face challenges in managing inter-individual and intra-individual pharmacokinetic differences.
Purpose of the Study:
- To explore strategies for reducing pharmacokinetic variability of anticancer agents.
- To identify key patient parameters influencing drug disposition and treatment outcomes.
- To propose a framework for personalized dosing of cancer therapies.
Main Methods:
- Reviewing existing literature on pharmacokinetic variability in oncology.
- Analyzing correlations between pharmacokinetic profiles and clinical outcomes.
- Investigating the role of genetic polymorphisms in drug metabolism and transport.
- Discussing mathematical modeling approaches for population and individual pharmacokinetics.
Main Results:
- Pharmacokinetic variability is a significant barrier to effective cancer chemotherapy.
- Patient-specific factors, including genetic makeup, are critical determinants of drug response.
- Mathematical modeling and personalized algorithms show promise in optimizing drug dosing.
Conclusions:
- Understanding patient-specific pharmacokinetic parameters is essential for improving cancer drug efficacy and safety.
- Personalized dosing strategies, informed by mathematical modeling, are needed to overcome pharmacokinetic variability.
- Further research into patient parameters and advanced modeling techniques will enhance antineoplastic treatment outcomes.
Related Concept Videos
01:22Nonlinear Pharmacokinetics: Causes of Nonlinearity
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
01:27Nonlinear Pharmacokinetics: Role of Transporters
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...